Shots:
- Health Canada has approved Nexsphere-F for the treatment of musculoskeletal pain embolization
- Nexsphere-F has launched the pivotal RESORB trial in the US post-IDE approval in 126 knee osteoarthritis pts comparing genicular artery embolization vs corticosteroid injections, with enrollment expected to complete in H1’26
- Nexsphere-F uses resorbable microsphere tech to temporarily block abnormal blood flow in pain-causing vessels, inducing nerve-ending necrosis within 2-8hrs. & provide rapid, lasting pain relief
Ref: NEXTBIOMEDICAL | Image: NEXTBIOMEDICAL | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
